Patents by Inventor Daniel Christopher Lopes

Daniel Christopher Lopes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein tyrosine-tyrosine analogs and methods of using the same
    Patent number: 11820803
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: November 21, 2023
    Assignee: Eli Lilly and Company
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
  • PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME
    Publication number: 20220025009
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
  • Protein tyrosine-tyrosine analogs and methods of using the same
    Patent number: 11155592
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: October 26, 2021
    Assignee: Eli Lilly and Company
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
  • PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME
    Publication number: 20200140514
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 7, 2020
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi